Home/Indications/Lower respiratory tract infections

Lower respiratory tract infections

0 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Lower respiratory tract infections has 0 FDA-approved novel treatments. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Phase 3 Readouts Pro

8 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q4 2026

Pirfenidone Capsules （400 mg）

Beijing Continent Pharmaceutical Co, Ltd.

Estimated · fresh NCT07388680

Q4 2026

Meropenem and Pralurbactam

Qilu Pharmaceutical Co., Ltd.

Estimated · aging NCT07089186

Q4 2027

BV100 (300 mg)

BioVersys SAS

Estimated · fresh NCT07326540

Unlock 5 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Lower respiratory tract infections Treatments by Mechanism

Top 5 mechanisms across 8 industry trials with a known mechanism of action.

See full pipeline →

Tetracycline-class Antibacterial

3 trials 2 sponsors

Fluoroquinolone Antibacterial

2 trials 2 sponsors

Interleukin-1 Receptor Antagonist

1 trials 1 sponsor

beta Lactamase Inhibitor

1 trials 1 sponsor

Interleukin-6 Antagonist

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Lower respiratory tract infections Clinical Pipeline by Phase

230 industry-sponsored trials across 125 sponsors

Showing 22 of 22 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Laboratorio Farmaceutico SIT srl	BUCCALIN®	—	RECRUITING	2027-04	NCT06736288
SamA Pharmaceutical Co., Ltd	Atock Dry Syrup with placebo patch	—	RECRUITING	2027-07	NCT06411925
Dr. Md. Alimur Reza	Faropenem	—	RECRUITING	2025-09-30	NCT06804096
Pfizer	Zavicefta, Ceftazidime-Avibactam	—	COMPLETED	2023-08-31	NCT04882085
Pfizer	Zavicefta, Ceftazidime-Avibactam	—	COMPLETED	2023-05-04	NCT04774094
Beijing Minhai Biotechnology Co., Ltd	PCV13	—	COMPLETED	2022-11-13	NCT06210737
China National Biotec Group Company Limited	COVAX+IIV4; COVAX+PPV23	—	COMPLETED	2021-09-05	NCT04790851
China National Biotec Group Company Limited	IIV4 and PPV23	—	COMPLETED	2020-11-26	NCT04559204
Bactiguard AB	—	—	COMPLETED	2020-05-08	NCT04242706
TaiGen Biotechnology Co., Ltd.	Nemonoxacin	—	COMPLETED	2020-03-23	NCT05133752
Yuria-Pharm	Rheosorbilact®	—	COMPLETED	2020-02-17	NCT03824457
Ahn-Gook Pharmaceuticals Co.,Ltd	Synatura® 15 mL	—	COMPLETED	2018-05-02	NCT03623282
Pfizer	13-valent Pneumococcal conjugate vaccine	—	COMPLETED	2015-07	NCT02034877
bene-Arzneimittel GmbH	Tacholiquine	—	COMPLETED	2015-01	NCT02515799
Forest Laboratories	Ceftaroline fosamil	—	COMPLETED	2014-05	NCT01669980
Pfizer	VACCINE: 13-valent pneumococcal conjugate vaccine	—	COMPLETED	2013-10	NCT00744263
Halyard Health	Opioid based analgesia	—	COMPLETED	2012-09	NCT00673712
Johnson & Johnson	doripenem	—	COMPLETED	2011-09-05	NCT00986102
Bayer	Avelox (Moxifloxacin, BAY12-8039)	—	COMPLETED	2010-12	NCT00656747
Janssen-Cilag Ltd.,Thailand	Doripenem	—	COMPLETED	2010-07	NCT00965848
Sanofi	PRISTINAMYCIN XRP7263	—	TERMINATED	2023-02-20	NCT02332577
Forest Laboratories	Ceftaroline fosamil	—	WITHDRAWN	2013-09	NCT01666743

Showing 98 of 98 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Qilu Pharmaceutical Co., Ltd.	Meropenem and Pralurbactam	—	RECRUITING	2026-12	NCT07089186
Beijing Continent Pharmaceutical Co, Ltd.	Pirfenidone Capsules （400 mg）	—	RECRUITING	2026-12-30	NCT07388680
BioVersys SAS	BV100 (300 mg)	—	RECRUITING	2027-12-30	NCT07326540
Qilu Pharmaceutical Co., Ltd.	Meropenem and Pralurbactam	—	RECRUITING	2028-06	NCT07327619
Biotest	Trimodulin	—	RECRUITING	2028-07-31	NCT05722938
Ansun Biopharma, Inc.	DAS181	—	RECRUITING	2028-09-01	NCT03808922
Materia Medica Holding	Raphamin	—	RECRUITING	2028-12-31	NCT07650227
Biomedica Foscama S.p.A. Industria Chimico-Farmaceutica	TAD® 600 mg/4 mL powder and solvent for solution for injection	—	RECRUITING	2025-06	NCT06296212
Zai Lab (Hong Kong), Ltd.	Omadacycline	—	RECRUITING	2025-01-01	NCT06162286
Fosun Adgenvax Biopharmaceutical Co.,Ltd.	13-valent pneumococcal conjugate vaccine (multivalent conjugate)	—	ACTIVE NOT RECRUITING	2025-06-30	NCT05759520
Nanjing Yoko Biomedical Co., Ltd.	YK-1169	—	NOT YET RECRUITING	2028-04-01	NCT07634198
Ahn-Gook Pharmaceuticals Co.,Ltd	AG2001	—	NOT YET RECRUITING	2026-03-31	NCT07198347
Yuhan Corporation	YHP2401	—	COMPLETED	2026-01-15	NCT07111468
AstraZeneca	Nirsevimab	—	COMPLETED	2025-11-24	NCT05110261
Meiji Seika Pharma Co., Ltd.	co-administration of cefepime and nacubactam	—	COMPLETED	2025-09-01	NCT05905055
Daewon Pharmaceutical Co., Ltd.	DW5121	—	COMPLETED	2025-05-27	NCT07093697
Materia Medica Holding	Raphamin	—	COMPLETED	2025-03-19	NCT06263881
Evopoint Biosciences Inc.	Combination of Imipenem/Cilastatin and XNW4107	—	COMPLETED	2024-09-29	NCT05204563
Paratek Pharmaceuticals Inc	Omadacycline	—	COMPLETED	2024-03-27	NCT04779242
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)	—	COMPLETED	2024-03-13	NCT06817187
Merck	V116	—	COMPLETED	2023-06-21	NCT05526716
Merck	V116	—	COMPLETED	2023-05-16	NCT05420961
Pfizer	ATM-AVI	—	COMPLETED	2023-02-23	NCT03329092
Aridis Pharmaceuticals, Inc.	AR-301	—	COMPLETED	2022-10-28	NCT03816956
Rigel Pharmaceuticals	Fostamatinib	—	COMPLETED	2022-09-05	NCT04629703
Merck	IMI/REL FDC	—	COMPLETED	2022-07-12	NCT03583333
Jiangsu Famous Medical Technology Co., Ltd.	Tanreqing capsule	—	COMPLETED	2022-06-02	NCT05305456
RAAS Nutritionals, LLC	Favipiravir	—	COMPLETED	2021-12-02	NCT05417997
Dompé Farmaceutici S.p.A	Reparixin	—	COMPLETED	2021-09-30	NCT04878055
Entasis Therapeutics	Sulbactam	—	COMPLETED	2021-07-26	NCT03894046
Hamad Medical Corporation	Anakinra	Interleukin-1 Receptor Antagonist [EPC]	COMPLETED	2021-03-01	NCT04643678
Biopharma Plasma LLC	IVIG	—	COMPLETED	2020-09-15	NCT04500067
Ahn-Gook Pharmaceuticals Co.,Ltd	AGS (Experimental)	—	COMPLETED	2020-07-29	NCT05344638
Merck	V114	—	COMPLETED	2020-04-03	NCT03950856
Basilea Pharmaceutica	ceftobiprole medocaril	—	COMPLETED	2020-03-16	NCT03439124
Merck	Imipenem	—	COMPLETED	2019-04-03	NCT02493764
Shionogi	Cefiderocol	—	COMPLETED	2019-04-01	NCT02714595
Shionogi	Cefiderocol	—	COMPLETED	2019-02-26	NCT03032380
Hyundai Pharm	Levotuss	—	COMPLETED	2018-10	NCT03489837
Hanlim Pharm. Co., Ltd.	HL301(Experimental)	—	COMPLETED	2018-09-21	NCT03654196
Melinta Therapeutics, Inc.	Delafloxacin	—	COMPLETED	2018-07-31	NCT02679573
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Tedizolid phosphate	—	COMPLETED	2018-06-22	NCT02019420
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	23-Valent Pneumococcal Polysaccharide Vaccine	—	COMPLETED	2018-06-07	NCT04278248
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Ceftolozane/tazobactam	—	COMPLETED	2018-05-15	NCT02070757
Nabriva Therapeutics AG	lefamulin	—	COMPLETED	2018-01	NCT02813694
R-Pharm	Nemonoxacin	—	COMPLETED	2017-12-13	NCT03551210
Walvax Biotechnology Co., Ltd.	7-valent pneumococcal conjugate vaccine	—	COMPLETED	2017-12-03	NCT02736240
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)	Vabomere	beta Lactamase Inhibitor [EPC]	COMPLETED	2017-07-21	NCT02168946
TaiGen Biotechnology Co., Ltd.	Nemonoxacin	—	COMPLETED	2017-05-04	NCT02205112
Bayer	Amikacin Inhalation Solution (BAY41-6551)	—	COMPLETED	2017-04-07	NCT01799993
Nabriva Therapeutics AG	lefamulin	—	COMPLETED	2017-04	NCT02559310
Paratek Pharmaceuticals Inc	Omadacycline	—	COMPLETED	2017-02-05	NCT02531438
Achaogen, Inc.	plazomicin	—	COMPLETED	2016-08-18	NCT01970371
Inmunotek S.L.	Biological vaccine	—	COMPLETED	2016-05	NCT01734811
Pfizer	ceftazidim-avibactam (CAZ-AVI, experimental product)	—	COMPLETED	2016-01	NCT01808092
Hyundai Pharmaceutical Co., LTD.	Acebrophylline	—	COMPLETED	2016-01	NCT02792946
Melinta Therapeutics, Inc.	Solithromycin	—	COMPLETED	2015-07	NCT01968733
GSK	Synflorix™	—	COMPLETED	2015-06-29	NCT01746108
Bayer	Ciprofloxacin (Cipro, BAYQ3939)	—	COMPLETED	2015-03	NCT01561794
Melinta Therapeutics, Inc.	Solithromycin	—	COMPLETED	2014-10	NCT01756339
Forest Laboratories	Ceftaroline fosamil	—	COMPLETED	2014-04	NCT01530763
Korea United Pharm. Inc.	KALOMIN™ Tab.	—	COMPLETED	2013-12	NCT02151734
GSK	Synflorix (3-Dose)	—	COMPLETED	2013-07-15	NCT01641133
Pfizer	Ceftaroline	—	COMPLETED	2013-05	NCT01371838
TaiGen Biotechnology Co., Ltd.	Levofloxacin	Fluoroquinolone Antibacterial [EPC]	COMPLETED	2012-08	NCT01529476
GSK	Pneumococcal conjugate vaccine Synflorix (GSK1024850A)	—	COMPLETED	2012-01-31	NCT00839254
GSK	Pneumococcal conjugate vaccine GSK1024850A	—	COMPLETED	2012-01-31	NCT00861380
GSK	Synflorix™( GSK1024850A)	—	COMPLETED	2011-07-26	NCT01153841
Pfizer	ampicillin sodium/sulbactam sodium	—	COMPLETED	2011-04	NCT01189487
Ahn-Gook Pharmaceuticals Co.,Ltd	Theobromine 300mg	—	COMPLETED	2011-02	NCT01416480
Ahn-Gook Pharmaceuticals Co.,Ltd	AG NPP709syrup	—	COMPLETED	2010-05	NCT01151202
Pfizer	Azithromycin	—	COMPLETED	2010-03	NCT00809328
GSK	Pneumococcal conjugate vaccine GSK1024850A	—	COMPLETED	2009-11-13	NCT00814710
GSK	Pneumococcal conjugate vaccine GSK 1024850A	—	COMPLETED	2009-10-05	NCT00907777
Bayer	Avelox (Moxifloxacin, BAY12-8039)	—	COMPLETED	2009-05	NCT00717561
Forest Laboratories	Ceftaroline fosamil for Injection	—	COMPLETED	2008-12	NCT00621504
GSK	GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)	—	COMPLETED	2008-11-10	NCT00609492
GSK	GSK1024805A	—	COMPLETED	2008-06-02	NCT00624819
Biotest	Trimodulin	—	TERMINATED	2025-05-05	NCT05531149
Dompé Farmaceutici S.p.A	Reparixin	—	TERMINATED	2024-07-29	NCT05254990
Aridis Pharmaceuticals, Inc.	Suvratoxumab	—	TERMINATED	2024-07-08	NCT05331885
PTC Therapeutics	PTC299	—	TERMINATED	2022-07-20	NCT04439071
RECORDATI GROUP	Siltuximab	Interleukin-6 Antagonist [EPC]	TERMINATED	2021-04-01	NCT04616586
AstraZeneca	Ravulizumab	—	TERMINATED	2021-02-08	NCT04369469
Dompé Farmaceutici S.p.A	Reparixin	—	TERMINATED	2020-11-27	NCT04794803
Polyphor Ltd.	Murepavadin	—	TERMINATED	2019-07-17	NCT03409679
Polyphor Ltd.	Murepavadin	—	TERMINATED	2019-07-17	NCT03582007
Melinta Therapeutics, Inc.	Solithromycin	—	TERMINATED	2018-03-21	NCT02605122
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Ceftolozane/Tazobactam	—	TERMINATED	2013-11-20	NCT01853982
Abbott Nutrition	—	—	TERMINATED	2012-11	NCT01477723
Johnson & Johnson	Cefepime	—	TERMINATED	2012-03	NCT01110421
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	Doripenem	—	TERMINATED	2011-06	NCT00589693
Venatorx Pharmaceuticals, Inc.	Cefepime-taniborbactam	—	WITHDRAWN	2027-06	NCT06168734
ImmunityBio, Inc.	Nogapendekin alfa inbakicept (NAI)	—	WITHDRAWN	2029-04-15	NCT07492875
Melinta Therapeutics, Inc.	Meropenem-Vaborbactam	—	WITHDRAWN	2020-06	NCT03006679
Durata Therapeutics Inc., an affiliate of Allergan plc	Dalbavancin	—	WITHDRAWN	2016-11	NCT02269644
Pfizer	Tigecycline	Tetracycline-class Antibacterial [EPC]	WITHDRAWN	2014-05	NCT01602874
Wyeth is now a wholly owned subsidiary of Pfizer	Tigecycline	Tetracycline-class Antibacterial [EPC]	WITHDRAWN	2014-05	NCT00914888

Showing 74 of 74 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Omnix Medical Ltd	OMN6	—	RECRUITING	2027-03	NCT06087536
Synairgen Research Ltd.	SNG001	—	RECRUITING	2027-04	NCT06999603
MiNK Therapeutics	agenT-797	—	RECRUITING	2027-06	NCT07615010
Vasomune Therapeutics, Inc.	AV-001 Injection	—	RECRUITING	2026-05	NCT05123755
Jiangsu HengRui Medicine Co., Ltd.	HRS-8427	—	RECRUITING	2026-02	NCT06841731
Shanghai SIMR Biotechnology Co., Ltd.	SR1375 capsule 3mg+regular treatments	—	RECRUITING	2025-10-15	NCT06577558
Mundipharma Research Limited	Co-Trimoxazole	—	RECRUITING	2025-05	NCT05835479
Eagle Pharmaceuticals, Inc.	CAL02	—	ACTIVE NOT RECRUITING	2026-02-10	NCT05776004
CanSino Biologics Inc.	24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) (referred to as PCV24) (dose M)	—	NOT YET RECRUITING	2026-11-24	NCT07600983
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	TQD3524	—	NOT YET RECRUITING	2027-07	NCT07512596
BioVersys AG	BV100 with 50 mg polymyxin B plus ceftazidime/avibactam	—	NOT YET RECRUITING	2028-03	NCT07431307
Aptarion Biotech AG	AON-D21	—	COMPLETED	2026-03-16	NCT05962606
Korea Arlico Pharm. Co., Ltd	ALC-2203-1	—	COMPLETED	2025-11-21	NCT07061925
GSK	AFX3772	—	COMPLETED	2025-09-18	NCT05412030
BioVersys AG	BV100 plus Polymyxin B	—	COMPLETED	2024-11-01	NCT05685615
Shionogi	Cefiderocol	—	COMPLETED	2024-09-17	NCT04215991
Enlivex Therapeutics Ltd.	Allocetra-OTS	—	COMPLETED	2024-01-12	NCT04612413
AstraZeneca	Tozorakimab	—	COMPLETED	2023-05-30	NCT04631016
Mirror Biologics, Inc.	AlloStim	—	COMPLETED	2023-03-01	NCT04441047
Shionogi	Cefiderocol	—	COMPLETED	2023-02-06	NCT04335539
LimmaTech Biologics AG	Kleb4V target dose	—	COMPLETED	2022-09-26	NCT04959344
MediciNova	Ibudilast	—	COMPLETED	2022-06-30	NCT04429555
Merck	V116	—	COMPLETED	2021-07-12	NCT04168190
CalciMedica, Inc.	Auxora (Part 1)	—	COMPLETED	2021-06-28	NCT04345614
Shaperon	NuSepin® 0.1 mg	—	COMPLETED	2021-04-13	NCT04565379
Kamada, Ltd.	Kamada Anti-SARS-CoV-2	—	COMPLETED	2020-11-26	NCT04550325
GSK	ASP3772	—	COMPLETED	2020-09-28	NCT03803202
Tigenix S.A.U.	Cx611	—	COMPLETED	2020-07-07	NCT03158727
Aridis Pharmaceuticals, Inc.	AR-105	—	COMPLETED	2019-04-25	NCT03027609
BioAegis Therapeutics Inc.	Recombinant Human Plasma Gelsolin	—	COMPLETED	2019-04-02	NCT03466073
MedImmune LLC	MEDI4893	—	COMPLETED	2018-10-02	NCT02296320
EmeraMed	Emeramide	—	COMPLETED	2018-05-30	NCT03123692
Biogen	Bardoxolone methyl	—	COMPLETED	2018-01-19	NCT02036970
Hanlim Pharm. Co., Ltd.	HL301	—	COMPLETED	2017-08-17	NCT03309800
Wockhardt	Nafithromycin 800 mg 3 days	—	COMPLETED	2017-07	NCT02903836
Merck	Prevnar 13®	—	COMPLETED	2016-07-01	NCT02037984
Aridis Pharmaceuticals, Inc.	KBSA301	—	COMPLETED	2016-05	NCT01589185
Genocea Biosciences, Inc.	GEN-004 with Aluminum Hydroxide Adjuvant	—	COMPLETED	2016-04	NCT02116998
Cardeas Pharma	Amikacin fosfomycin inhalation solution	—	COMPLETED	2016-03	NCT01969799
PharmaKing	N02RS1 1200mg	—	COMPLETED	2016-03	NCT02637310
Polyphor Ltd.	POL7080	—	COMPLETED	2015-12	NCT02096328
Biotest	BT086	—	COMPLETED	2015-02	NCT01420744
Hanlim Pharm. Co., Ltd.	HL301 300mg capsule	—	COMPLETED	2014-07	NCT02250027
TaiGen Biotechnology Co., Ltd.	Nemonoxacin 500 mg	—	COMPLETED	2013-12	NCT01944774
PharmaKing	Combination of Broussonetia spp and Lonicera spp	—	COMPLETED	2013-11	NCT01979926
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Faropenem（high dose group）	—	COMPLETED	2012-07	NCT01886053
Yuhan Corporation	YHD001 dose level 1	—	COMPLETED	2012-05	NCT01420445
Melinta Therapeutics, Inc.	Levofloxacin	Fluoroquinolone Antibacterial [EPC]	COMPLETED	2011-07	NCT01168713
AstraZeneca	AZD5069 50mg	—	COMPLETED	2011-03	NCT01233232
TaiGen Biotechnology Co., Ltd.	Nemonoxacin 3 tablets	—	COMPLETED	2010-08	NCT01537250
ADMA Biologics, Inc.	RI-001	—	COMPLETED	2010-05	NCT00632463
Valneva Austria GmbH	IC43	—	COMPLETED	2010-02	NCT00876252
Kenta Biotech Ltd	KBPA-101	—	COMPLETED	2009-07	NCT00851435
Pfizer	sulopenem and PF-03709270	—	COMPLETED	2009-06	NCT00797108
Mesoblast, Inc.	Prochymal™	—	COMPLETED	2009-03-09	NCT00683722
Humanigen, Inc.	KB001	—	COMPLETED	2009-03	NCT00691587
Senhwa Biosciences, Inc.	CX-4945 (SARS-CoV-2 domain)	—	TERMINATED	2025-04-22	NCT06202521
Bristol-Myers Squibb	CC-90001	—	TERMINATED	2021-12-24	NCT03142191
CalciMedica, Inc.	CM4620-IE (Injectable Emulsion)	—	TERMINATED	2021-12-21	NCT04661540
Celularity Incorporated	CYNK-001	—	TERMINATED	2021-08-30	NCT04365101
Ionis Pharmaceuticals, Inc.	ION-827359	—	TERMINATED	2021-04-27	NCT04441788
PhaseBio Pharmaceuticals Inc.	Pemziviptadil (PB1046)	—	TERMINATED	2020-12-02	NCT04433546
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.	UNIKINON (Chloroquine phosphate) 200mg tablets	—	TERMINATED	2020-11-30	NCT04344951
Eli Lilly	LY3127804	—	TERMINATED	2020-10-12	NCT04342897
Arsanis, Inc.	ASN100	—	TERMINATED	2018-07-19	NCT02940626
Thrombologic ApS	Ilomedin and Integrilin	—	TERMINATED	2014-03	NCT01532544
IASO Pharma Inc.	Zabofloxacin	—	TERMINATED	2012-04	NCT01081964
Furiex Pharmaceuticals, Inc	JNJ-32729463	—	TERMINATED	2011-10	NCT01198626
Pfizer	tigecycline	Tetracycline-class Antibacterial [EPC]	TERMINATED	2011-06	NCT00707239
Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Jaktinib hydrochloride tablets	—	WITHDRAWN	2024-04-23	NCT05702788
CalciMedica, Inc.	Auxora	—	WITHDRAWN	2022-07	NCT05171920
Beyond Air Inc.	—	—	WITHDRAWN	2020-11-15	NCT04456088
Cardeas Pharma	Amikacin Fosfomycin Inhalation Solution	—	WITHDRAWN	2015-12	NCT02218359
Boehringer Ingelheim	BIBW 2948 BS	—	WITHDRAWN	2008-09	NCT00726479

Showing 36 of 36 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Cho Pharma Inc.	Glyconjugate Klebsiella pneumoniae bivalent vaccine	—	RECRUITING	2026-11-05	NCT07016152
Pfizer	Ibuzatrelvir co-process API film coated tablet	—	RECRUITING	2026-06-03	NCT07552779
GSK	Pn-MAPS30plus	—	ACTIVE NOT RECRUITING	2026-12-09	NCT07428759
NextCell Pharma Ab	ProTrans®	—	ACTIVE NOT RECRUITING	2027-03-31	NCT04896853
Pfizer	PG4 vaccine in Buffer 1 with low dose PA-001	—	ACTIVE NOT RECRUITING	2027-10-21	NCT07086677
MicrobiotiX Co., Ltd	MP101	—	NOT YET RECRUITING	2026-12	NCT07492771
GSK	Pn-MAPS30plus	—	NOT YET RECRUITING	2027-02-22	NCT07406334
GSK	Pn-MAPS30plus	—	NOT YET RECRUITING	2028-04-03	NCT07406347
Op-T LLC	OPT101	—	NOT YET RECRUITING	2026-04	NCT06669403
GSK	Pn-MAPS30plus	—	COMPLETED	2026-05-06	NCT07105722
GPN Vaccines	Gamma PN3	—	COMPLETED	2025-03-31	NCT06562790
Merck	Ceftolozane/Tazobactam	—	COMPLETED	2024-09-14	NCT04223752
CanSino Biologics Inc.	PBPV	—	COMPLETED	2023-09-14	NCT05622942
Heronova Pharmaceuticals	Remdesivir	—	COMPLETED	2023-03-27	NCT06860282
Institute of Vaccines and Medical Biologicals, Vietnam	COVIVAC	—	COMPLETED	2021-06-06	NCT04830800
Paratek Pharmaceuticals Inc	Omadacycline	—	COMPLETED	2020-03-23	NCT04160260
LimmaTech Biologics AG	Bioconjugate pneumococcal vaccine	—	COMPLETED	2018-09-12	NCT03303976
Melinta Therapeutics, Inc.	Delafloxacin	—	COMPLETED	2018-07-19	NCT03534622
Combioxin SA	CAL02 Low-dose	—	COMPLETED	2018-02-20	NCT02583373
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	Ceftolozane/Tazobactam - Multiple Doses	—	COMPLETED	2017-06-15	NCT02387372
Meiji Seika Pharma Co., Ltd.	ME1100 inhalation solution	—	COMPLETED	2017-03-22	NCT02459158
Tetraphase Pharmaceuticals, Inc	TP-271	—	COMPLETED	2016-09-28	NCT02724085
Dompé Farmaceutici S.p.A	SCMC-lys powder 1.35 g	—	COMPLETED	2016-07-25	NCT02858193
MedImmune LLC	MEDI3902 - Dose 1	—	COMPLETED	2015-04-20	NCT02255760
Genocea Biosciences, Inc.	GEN-004 Low Dose	—	COMPLETED	2015-02	NCT01995617
Sanofi	Pneumococcal Vaccine High Dose (Formulation 1)	—	COMPLETED	2013-03	NCT01446926
Sanofi	Pneumococcal vaccine Formulation 1	—	COMPLETED	2011-01	NCT01444352
Sanofi	Pneumococcal Vaccine Formulation 1	—	COMPLETED	2010-09	NCT01444339
Pfizer	CP-70,429 and PF-03709270	—	COMPLETED	2010-03	NCT00759564
GSK	GSK2231395A	—	COMPLETED	2009-05-04	NCT00814489
Clarametyx Biosciences, Inc.	CMTX-101	—	TERMINATED	2024-08-02	NCT05629741
Pfizer	Ceftazidime-avibactam	—	TERMINATED	2021-04-09	NCT04040621
Shionogi	Cefiderocol	—	TERMINATED	2019-10-08	NCT03862040
Basilea Pharmaceutica	Ceftobiprole	—	TERMINATED	2009-11	NCT00771719
GSK	GSK2231395A	—	TERMINATED	2009-04-07	NCT00849069
Merck	Frespaciguat	—	WITHDRAWN	2020-11-10	NCT04425733

Precision Medicine Biomarkers

All biomarkers →

Biomarkers used for patient selection in Lower respiratory tract infections

Beta-lactamase-producing bacteria (3) β-lactamase–negative bacteria (1)

Novel Lower respiratory tract infections Drugs by Company (New molecular entities)

No novel drugs found for this indication.

Reformulations (4 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

TYZAVAN

Hikma

T5 2019

CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER